New Multi-Center Study Shows equicenta® CTM, Ready-to-Use, Equine Umbilical Cord Allograft Outperforms Standard of Care in Returning Performance Horses to Work
Equine Performance Labs (EPL), the team behind equicenta® CTM — announced the publication of a peer-reviewed, prospective, controlled clinical trial demonstrating that a single, ready-to-use injection of equicenta® CTM produced significantly better clinical outcomes than clinician-selected standard of care (SOC) in lame performance horses. The study was accepted June 29, 2026 in Frontiers in Veterinary Science (Veterinary Regenerative Medicine section) and represents one of the most rigorous multi-center evaluations of a regenerative therapy in equine practice to date.
Equine Performance Labs Announces Publication of Landmark Study in BMC Medicine Demonstrating Safety, Consistency, and Clinical Promise of equicent™ CTM Umbilical Cord Allograft
Equine Performance Labs (EPL) is proud to announce the publication of a pivotal peer-reviewed study in BMC Medicine ("Cryopreserved equine umbilical cord tissue allograft characterization and biocompatibility in vivo in musculoskeletal tissues: a controlled study"), highlighting the safety, consistency, and biological innovation of its proprietary injectable allograft, equicent™ CTM, for equine musculoskeletal repair.[1][2]
